---
title: "BETTA PHARMACEUTICALS: The company is accelerating the overseas commercial plan for ensartinib"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247270318.md"
description: "On July 4th, BETTA PHARMACEUTICALS stated on the interactive platform that the company is currently accelerating the overseas commercial plan for ensartinib, actively exploring promotional models that comply with local regulations and market demands to achieve drug accessibility and maximize company benefits"
datetime: "2025-07-04T08:45:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247270318.md)
  - [en](https://longbridge.com/en/news/247270318.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247270318.md)
generator: "portal-rs"
---

# BETTA PHARMACEUTICALS: The company is accelerating the overseas commercial plan for ensartinib

On July 4th, BETTA PHARMACEUTICALS stated on the interactive platform that the company is currently accelerating the overseas commercial plan for ensartinib, actively exploring promotional models that comply with local regulations and market demands to achieve drug accessibility and maximize company interests

### Related Stocks

- [300558.CN](https://longbridge.com/en/quote/300558.CN.md)
- [0BDYY.HK](https://longbridge.com/en/quote/0BDYY.HK.md)

## Related News & Research

- [The 10-year Treasury yield is breaking out and 5% could be just the beginning. Here's why that matters.](https://longbridge.com/en/news/297548327.md)
- [Ocumension says China regulator accepts domestic filing for dexamethasone eye injection OT-502](https://longbridge.com/en/news/297648398.md)
- [Fed chair Warsh’s hawkish Jackson Hole turn favours soaring banks over struggling S-Reits](https://longbridge.com/en/news/297426473.md)
- [Manufacturers are getting frustrated: 'The economy is annoying'](https://longbridge.com/en/news/297685808.md)
- [Manufacturers are getting frustrated: 'The economy is annoying'](https://longbridge.com/en/news/297686341.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**